Reported Saturday, MoonLake's Phase 3 VELA Trials Show Sonelokimab Achieves 62% HiSCR75 And Up To 32% HiSCR100 At Week 40 In Moderate-To-Severe Hidradenitis Suppurativa

MoonLake's Phase 3 VELA trials for sonelokimab (SLK) in treating moderate-to-severe hidradenitis suppurativa (HS) reported that 62% of patients achieved HiSCR75 and up to 32% achieved HiSCR100 at Week 40. Additionally, 25% of patients reached inflammatory remission, and significant improvements were noted in quality of life metrics. No new safety concerns were identified during the trials, with detailed results set to be presented at the 2026 AAD Annual Meeting.